April 17th 2024
A recent meta-analysis found that multiparametric MRI and PET/CT had comparable detection rates for diagnosing prostate cancer recurrence.
Multinational Study Suggests High Variability with Quality of Prostate MRI
October 12th 2023In a study of 355 multiparametric prostate MRI exams from a total of 71 scanners from 41 facilities in 18 countries, researchers found that only 23 scanners achieved a PI-QUAL score of 5 for optimal image quality.
Emerging Insights in Diagnosing Recurrent Prostate Cancer in Men with Low PSA Levels
October 7th 2023In a recent video interview, Ashesh Jani, M.D., discussed a subset analysis from the SPOTLIGHT trial that examined the utility of the PET PSMA agent flotufolastat F 18 (Posluma) for detecting prostate cancer recurrence in men with low PSA levels lower than 1 ng/mL.
CMS Issues New Reimbursement Code for PSMA PET Agent POSLUMA
September 26th 2023The transitional pass-through payment reimbursement code for the FDA-approved PSMA PET agent for prostate cancer detection will be effective as of October 1, according to the Centers for Medicare and Medicare Services (CMS).
Can a Deep Learning Algorithm Enhance Detection of Prostate Cancer Recurrence with Biparametric MRI?
September 26th 2023For patients who had previous radiotherapy for prostate cancer (PCa), researchers found that a biparametric MRI-based deep learning model demonstrated an 81.5 percent sensitivity rate for PCa recurrence in patients previously treated with external beam radiation treatment (EBRT) and 100 percent sensitivity in patients with greater than 34 ml in gland volumes.
Study: PET/CT Multivariate Model Enhances Accuracy for Diagnosing Prostate Cancer
September 13th 2023For men with PSA scores between 4 to 10 ng/mL, a multivariate prediction model that incorporates 68Ga-PSMA PET/CT had a 92.7 AUC for predicting clinically significant prostate cancer, according to newly published research.
Study: 'All Men with PSAs Between 3 and 20 ng/mL Should Undergo MRI Before Biopsy'
September 7th 2023In a study of over 23,000 men who had PSA testing, researchers found that the adoption of pre-biopsy MRI resulted in a 21 percent decrease in negative biopsies and a 37 percent increase in the proportion of diagnosed Gleason score 7 to 10 prostate cancers.
AI Can Improve Tumor Mapping, Aid Patient Counseling in Focal Therapy for Prostate Cancer
August 31st 2023Wayne G. Brisbane, MD, of the University of California, Los Angeles, discussed the challenges of focal therapy for prostate cancer and how Unfold AI can help improve the accuracy of this treatment, as well as help counsel patients during the treatment decision process.
Study: 66 Percent of Men with Positive MRI for Prostate Cancer Had Normal PSA Levels
August 23rd 2023Two-thirds of men with a positive screening MRI for prostate cancer had PSA levels below 3 ng/mL and 91 percent of these men had clinically significant prostate cancer, according to newly published research.
Is Pre-Imaging Biopsy Necessary for Prostate Cancer Staging in Elderly Patients?
August 17th 2023For patients 80 years of age or older that have a PSA level at 20 ng/mL or higher, PSMA PET/CT has a high likelihood of success in diagnosing and staging prostate cancer regardless of pre-imaging biopsy use, according to newly published research.
Study: Abbreviated Non-Contrast MRI May Facilitate Early Detection of Prostate Cancer
August 11th 2023The use of non-contrast, biparametric MRI (bpMRI) for prostate cancer screening regardless of PSA values detected more clinically significant cases of prostate cancer than reserving bpMRI for patients with elevated PSA levels, according to preliminary findings from an ongoing prospective, randomized study.
Study: Combination of Ultrasound and MRI-Targeted Biopsy Enhances Detection of Prostate Cancer
July 31st 2023In a study of 413 men with suspected prostate cancer, researchers found the combination of ultrasound and multiparametric MRI-targeted biopsy with systematic biopsy diagnosed prostate cancer in 72.9 percent of patients in comparison to 60.2 percent with systematic biopsy alone.
Can Low-Dose CT Have an Impact in Diagnosing Bone Metastasis in Patients with Prostate Cancer?
July 27th 2023In a study of 601 patients with prostate cancer, researchers found that only one patient with extensive metastasis was falsely diagnosed as non-metastatic on whole-body, low-dose computed tomography (CT) by reviewing radiologists.
Meta-Analysis Compares MRI-Guided SBRT and CT-Guided SBRT for Prostate Cancer
July 24th 2023A newly published review of 29 prospective studies revealed the use of MRI-guided daily adaptive SBRT in the management of prostate cancer was associated with significantly lower risks of acute grade 2 or higher genitourinary (GU) and gastrointestinal (GI) toxicities in comparison to CT-guided non-adaptive SBRT.
Can an Emerging System Have an Impact in Assessing Treatment Response for Prostate Cancer?
July 13th 2023Examining the use of the Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT (RECIP 1.0) model for assessing the treatment of metastatic castration-resistant prostate cancer, researchers found robust agreement between quantitative application of RECIP via tumor segmentation software and qualitative application of the model through reads by nuclear medicine physicians.
Can Pre-Op MRI Staging Help Predict Prostate Cancer Recurrence after a Prostatectomy?
July 10th 2023Patients with extraprostatic extension (EPE) on pre-prostatectomy MRI had a 3.6-fold higher risk for biochemical recurrence (BCR) of prostate cancer and a 25 percent lower three-year BCR-free survival rate in comparison to patients without EPE on pre-op MRI, according to newly published research.
Clarity Pharmaceuticals to Begin Phase 3 Trial for New PSMA PET Agent for Prostate Cancer
July 5th 2023The prospective multicenter trial, which is slated to begin patient recruitment in late 2023, will reportedly assess the ability of 64Cu SAR-bisPSMA to diagnose prostate cancer within pelvic lymph nodes.